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The two-pore domain K channel, TRESK (TWIK-related spi-
nal cord K channel) is activated in response to the calcium sig-
nal by the calcium/calmodulin-dependent protein phosphatase,
calcineurin. In the present study we report that calcineurin also
interacts with TRESK via an NFAT-like docking site, in addition to
its enzymatic action. In its intracellular loop, mouse TRESK pos-
sesses the amino acid sequence, PQIVID, which is similar to the
calcineurin binding consensus motif, PXIXIT (where X denotes any
amino acids), necessary for NFAT (nuclear factor of activated
T cells) activation and nuclear translocation. Mutations of the
PQIVID sequence of TRESK to PQIVIA, PQIVAD, or PQAVAD
increasingly deteriorated the calcium-dependent activation in the
listed order and correspondingly reduced the benzocaine sensitivity
(a property discriminating activated channels from resting ones),
when it was measured after the calcium signal in Xenopus oocytes.
Microinjection of VIVIT peptide, designed to inhibit the NFAT-
calcineurin interaction specifically, also eliminated TRESK activa-
tion. The intracellular loop of TRESK, expressed as a GST fusion
protein, bound constitutively active calcineurin in vitro. PQAVAD
mutation as well as addition of VIVIT peptide to the reaction abro-
gated this calcineurin binding. Wild type calcineurin was recruited
to GST-TRESK-loop in the presence of calcium and calmodulin.
These results indicate that the PQIVID sequence is a docking site
for calcineurin, and its occupancy is required for the calcium-de-
pendent regulation of TRESK. Immunosuppressive compounds,
developed to target the NFAT binding site of calcineurin, are also
expected to interfere with TRESK regulation, in addition to their
desired effect on NFAT.
Two-pore domain potassium (2PK)3 channels give rise to back-
ground (leak) potassium conductance and their diverse regulatory
mechanisms control cellular function by adjusting both the resting
membrane potential and excitability (for review, see Refs. 1 and 2).
TRESK (TWIK-related spinal cordK channel) is uniquely regulated by
the calcium signal among the 2PK channels. We have recently
reported that TRESK, expressed heterologously in Xenopus oocytes, is
activated about 10-fold by the calcium/calmodulin-dependent protein
phosphatase, calcineurin (3). TRESK was cloned from human spinal
cord (4) and mouse cerebellum (3), and its expression was also demon-
strated by reverse transcription-PCR in cerebrum, brainstem, testis,
pancreas, and placenta (5–7). A massive signal was detected by North-
ern blot in rat thymus and spleen (7). Single channel activity of TRESK
has recently been demonstrated in dorsal root ganglion neurons (8). In
the absence of specific antibodies and inhibitors, TRESK has neither
been identified at the protein level nor has it been detected as an endog-
enous whole cell current. However, the robust activation of TRESK by
the calcium signal implicates that it can influence substantially the func-
tion of the native cells expressing the channel.
The calcineurin-mediated regulation suggests that TRESK activation
is the target of the widely used immunosuppressive drugs, cyclosporine
A and FK506, as it was, in fact, demonstrated in Xenopus oocytes (3).
These drugs inhibit calcineurin (and consequentlyNFATactivation and
interleukin-2 production of T lymphocytes) by forming inhibitory com-
plexes with the ubiquitous immunophilin proteins (9, 10). However,
general inhibition of calcineurin also causes several undesired effects.
Therefore, a novel direction of drug development focuses on theNFAT-
docking site of calcineurin, which is considered to be a more specific
target than the phosphatase activity (11, 12). The binding of calcineurin
to the PXIXIT consensus motif (where X denotes any amino acid) is
required forNFATactivation. Apart fromNFAT, the only knownmam-
malian proteins possessing similar calcineurin binding sites are cal-
cineurin inhibitors/modulators or anchoring proteins (13, 14). In the
present study we report for the first time that an ion channel, TRESK,
has an NFAT-like calcineurin binding consensus sequence and the
binding of the phosphatase to this docking site is indispensable for the
regulation of the channel. Therefore the inhibitors, designed to block
the calcineurin-NFAT interaction specifically, may also interfere with
TRESK activation.
EXPERIMENTAL PROCEDURES
Materials—VIVIT peptide (NFAT inhibitor) and calcineurin autoin-
hibitory peptide (ITSFEEAKGLDRINERMPPRRDAMP) were pur-
chased from Calbiochem, bovine calcineurin and calmodulin from
Sigma. Enzymes and kits of molecular biology applications and all other
chemicals of analytical grade were obtained from the companies listed
elsewhere (3).
GST-TRESK Loop Fusion Proteins—To produce GST-TRESKloop
protein, the cDNA encoding the intracellular loop of mouse TRESK
(amino acids 164–292) was PCR-amplified from our pEXO-TRESK
plasmid (3), applying consecutively Loop-s1/Loop-a1 and Loop-s2/
Loop-a1 primer combinations (see the sequences and cloning sites in
Table 1). The PCR product was ligated into the XhoI site of pGEX-4T-1
(Amersham Biosciences, Little Chalfont, UK). To obtain the longer
GST-TRESKloop-TAPtag protein, TRESK loop was amplified with
Loop-s1 and Loop-a2 oligonucleotides. The PCR product was cloned
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into the pcDNA3-TAPtag plasmid (Séraphin Laboratory, EMBL,
Heidelberg, Germany). The fused TRESKloop-TAPtag coding region
was amplified with the Loop-s2/TAP-a primer combination and
ligated into the SalI site of pGEX-6P-3 (Amersham Biosciences).
QuikChangeTM in vitro site-directed mutagenesis was performed as
described previously (3).
The GST-TRESKloop fusion constructs were expressed in BL21
strain ofEscherichia coli. Bacteriawere sonicated in bufferA, containing
in mM: 50 NaCl, 50 KCl, 1 EDTA, 1 PMSF, 0.1 benzamidine, 1 dithio-
threitol, 50 Tris-HCl (pH 7.6). The lysate was centrifuged and the GST
fusion protein was affinity-purified from the supernatant by glutathi-
one-agarose (Sigma).
Recombinant, Constitutively Active Calcineurin—The hexahistidine-
tagged constitutively active calcineurin was produced by amodification
of the methods reported previously (15). Coding regions of the trun-
cated mouse calcineurin A (-isoform, amino acid residues 1–398) and
human calcineurin B subunits were amplified from pBJ5-CnA-FL and
pBJ5-CnB plasmids (16), applying the mCnA-s/mCnAdel-a and hCnB-
s/hCnB-a primer combinations, respectively. The calcineurin A and B
products were ligated into the same pET15b vector (Novagen), between
theNdeI and BamHI sites. BL21 strain of E. coliwas cotransformedwith
pBB131 (encoding myristoyl-CoA:protein N-myristoyltransferase (17,
18), formodifying calcineurin B post-translationally) and the bicistronic
plasmid encoding calcineurin A and B. Bacteria were grown in LB con-
taining 50g/ml kanamycin and 130g/ml ampicillin and inducedwith
isopropyl -D-thiogalactopyranoside (0.5 mM) in the presence of myr-
istic acid (0.24mM) for 3 h. Bacteria were sonicated in buffer B, contain-
ing: 200 NaCl, 2 MgCl2, 1 EGTA, 5.5 -mercaptoethanol, 30 phosphate
(pH 7.8 with NaOH), supplemented with 1 PMSF, 0.2 benzamidine, 5
imidazole (inmM) and 30 soybean trypsin inhibitor (type IIS, Sigma), 16
leupeptin, 11 aprotinin (in g/ml). The lysate was centrifuged, and the
protein was purified from the supernatant by nickel-nitrilotriacetic
acid-agarose (Qiagen); after binding for 1 h the resin was washed six
times with 14 ml of buffer B, containing 0, 20, and 50 mM imidazole, in
the first, second, and third pair of washing steps, respectively. Cal-
cineurin was eluted by 5  0.5 ml of 250 mM imidazole in buffer B and
dialyzed against 140 mM KCl, 2 mM MgCl2, 1 mM EGTA, 0.1 mM dithi-
othreitol, 20 mM Tris-HCl (pH 7.3) and stored at 70 °C.
GST Pulldown Assay—Ten l of the 50% resin suspension of the
appropriate GST fusion protein was incubated for 1 h with or without
full-length bovine calcineurin (1.5 g), recombinant constitutively
active calcineurin (5–10 g), calmodulin (2.5 g), VIVIT peptide (200
M), calcineurin autoinhibitory peptide (200 M), CaCl2 (0.25 mM), in
the presence of 1% Triton X-100. The final volume was adjusted with a
buffer containing (in mM): 50 NaCl, 50 KCl and 50 Tris-HCl (pH 7.6)
(plus 1mMEDTA in the reactions containing recombinant calcineurin).
The resin was washed twice with 150 l of assay buffer, also containing
1% Triton X-100 in the first wash, and 0.3 mM CaCl2 if full-length cal-
cineurinwas used. The bound proteins were analyzed on 12% polyacryl-
amide gels stained with Coomassie Brilliant Blue or silver, according to
Heukeshoven and Dernick (19).
Handling of Xenopus laevis Oocytes and Two-electrode Voltage Clamp
Measurements—The oocytes were prepared, the cRNAwas synthesized,
and microinjected and two-electrode voltage clamp measurements
were performed as described previously (3). The low [K] solution con-
tained (in mM): 95.4 NaCl, 2 KCl, 1.8 CaCl2, 5 HEPES (pH 7.5 with
NaOH). The high [K] solution contained 80mMK (78mMNa of the
low [K] solution was replaced with K). The voltage protocol for
measuring TRESK current and the calcium-activated chloride current
simultaneously was as following:100mV for 300ms, 0mV for 250ms,
and 20 mV for 300 ms, applied every 3 s from a holding potential of 0
mV. TRESK current and the calcium-activated chloride current (ICl,Ca)
weremeasured at the end of the voltage steps to100mV and20mV,
respectively. As we reported previously (20, 21), ICl,Ca at100mV in 80
mM [K] was negligible compared with the robust K current of
expressed 2PK channels. Thus ICl,Ca was estimated by applying voltage
steps to 20 mV, which is close to the K equilibrium potential. The
initial ICl,Ca could be measured independently from the K current,
since TRESK activation was delayed compared with the onset of ICl,Ca.
All treatments of the animals were conducted in accordance with
state laws and institutional regulations. The experiments were
approved by the Animal Care and Ethics Committee of the Semmel-
weis University.
Statistics and Calculations—Data are expressed as means  S.E. Sta-
tistical significance was estimated by t test for dependent or independ-
ent samples, one-way ANOVAor two-way repeatedmeasures ANOVA
and Scheffe’s test for pairwise post hoc comparisons using the Statistica
6.0 program package (StatSoft, Tulsa, OK). The difference was consid-
ered to be significant at p  0.05. Free [Ca2] was calculated with Che-
lator program (written by Theo J. M. Schoenmakers, University of
Nijmegen,Nijmegen, TheNetherlands). Some sequence operations (e.g.
automatic design of silent mutations to QuikChange primers for select-
ing the mutant clones) were performed with the sequence-handling
program “SeqHandler” developed in our laboratory.
RESULTS
The LocalAnesthetic BenzocaineDistinguishesActivatedTRESK from
the Resting Channels—Reduced stimulation of a mutant TRESK chan-
nel by the calcium signal may reflect the impaired mechanism of
calcineurin-dependent activation. However, a constitutively active
mutant channel, which is nearlymaximally active even under basal con-
ditions, is also expected to be unresponsive to the calcium signal. To
TABLE 1
Oligonucleotide sequences for PCR and in vitro site-directed mutagenesis
Start codons are in italic. Restriction enzyme sites for cloning or those introduced by silent mutations for identifyingmutant clones are underlined.Mutations of the coding
sequence are marked with lowercase letters.
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discriminate between these two mutant types, we searched for a phar-
macological tool, which affects distinctly the basal and the calcineurin-
activated currents.
TRESK current was measured in 80 mM extracellular K concentra-
tion at 100 mV with the two-electrode voltage clamp technique. The
calcium signal evoked by ionomycin (0.5 M) resulted in a 9.4  1-fold
activation of TRESK (n  5). Benzocaine (1 mM) inhibited TRESK cur-
rent significantly less before (13  2%) than after the application of
ionomycin (51  1%, p  0.001, Student’s t test for dependent samples,
Fig. 1). This indicates that benzocaine inhibits stimulated wild type
TRESK preferentially and it can be applied to determine, whether a
givenmacroscopic TRESK current is constituted by resting or activated
channels.
We also tested the effect of benzocaine on S276A mutant TRESK,
which had been reported to be a constitutively active form of the chan-
nel, being unresponsive to the calcium signal (3). The resting current of
S276A TRESK was inhibited by benzocaine (51  1%, n  6, Fig. 1B)
identically to the current of the activated wild type channel. The strong
inhibition of S276A mutant verified that benzocaine could be used for
differentiating the two types of mutant TRESK channels, both of which
are characterized by apparent insensitivity to the calcium signal. The
constitutively active TRESKmutants are expected to be inhibited more
effectively by the local anesthetic than the mutants of really impaired
activation.
Mutations of the PQIVID Sequence of TRESK Prevent the Calcium-
dependent Activation—In its intracellular loop, mouse TRESK pos-
sesses the PQIVID sequence (amino acids 210–215), which is highly
similar to the calcineurin binding consensus motif (PXIXIT) of NFAT
proteins. To examine the role of this motif in the calcium-dependent
regulation, differentmutants of TRESK channel were created by replac-
ing distinct amino acid residues of the PQIVID sequence with alanines.
Since the mutation of a proline residue often results in major structural
changes and apart from the proline only the two isoleucines match
directly to the PXIXIT consensusmotif, wemutated one or both of these
isoleucines (PQIVAD and PQAVAD mutants). In addition, we also
examined the PQIVIA mutant to elucidate whether the aspartate resi-
due, which does not correspond to the NFAT consensus motif, can
substitute for the threonine and strengthen the binding to calcineurin.
Expression of all the mutants yielded functional channels in Xenopus
oocytes; however, their responses to the calcium signal, evoked by the
calcium ionophore ionomycin, were affected (Fig. 2A). The response of
the PQIVIAmutant was attenuated (4.1  0.3-fold activation (n 5) in
contrast to the 7.5 0.6-fold (n 6) increase of the wild type), suggest-
ing that the aspartate residue promoted the binding of calcineurin, and
its mutation to alanine decreased the affinity to the phosphatase. Muta-
tion of the second isoleucine of the motif (PQIVADmutation) strongly
reduced the ionomycin-evoked activation (only 1.6  0.1-fold increase,
n  5). The mutation of both critical isoleucines (PQAVAD) had an
even stronger effect; the calcium-dependent regulation was completely
eliminated (1.1  0.1-fold current after the stimulation, n  5, Fig. 2A).
The reduced response of the mutant channels to the calcium signal
suggests that the PQIVID sequence of TRESK, similarly to the PXIXIT
motifs of NFAT proteins, is a functionally important calcineurin dock-
ing site.
FIGURE 1. Differential inhibition of resting and activated TRESK channels by benzo-
caine. A, currents of an oocyte expressing mouse TRESK were measured at the end of
300-ms voltage steps to 100 mV applied every 3 s from 0 mV holding potential. (The
extracellular [K] was changed from 2 to 80 mM and back, as indicated.) TRESK current
was stimulated with ionomycin (0.5 M, gray bar). Sensitivity of TRESK to benzocaine
(1 mM) was tested with brief applications of the anesthetic, as indicated by black bars. B,
statistical representation of the inhibition of wild type TRESK evoked by benzocaine
before and after ionomycin stimulation. The inhibition of the current of S276A constitu-
tively active mutant of TRESK by benzocaine is also shown. (The current of the S276A
mutant has not been stimulated with ionomycin.) The numbers in the bars indicate the
number of measured oocytes.
FIGURE 2. Mutations of the PQIVID motif reduce the activation induced by ionomy-
cin, stimulation of M1 muscarinic acetylcholine receptor, or microinjection of a sat-
urated calcium buffer. A, TRESK currents of the oocytes expressing the wild type (wt,
PQIVID), PQIVIA, PQIVAD, or PQAVAD mutant channels (as indicated on the right side)
were stimulated with ionomycin (Iono., 0.5 M, gray bar). After ionomycin application,
the currents were inhibited with benzocaine (Benzo., 1 mM, black bar). TRESK currents
were normalized to the resting value measured at 0 min. All the mutant channels were
statistically different from the wild type in the respect of their ionomycin activation and
benzocaine sensitivity (n  5– 6, p  0.001). B, wild type or the same mutant TRESK
channels as in A were coexpressed with M1 muscarinic receptor. The oocytes were stim-
ulated with carbachol (1 M) as indicated by the gray bar. The activation of the PQIVAD
and PQAVAD mutants was significantly smaller than that of the wild type (n  5 each, p 
0.01). C, the oocytes expressing the wild type or the mutant channels were microinjected
(as indicated by the vertical arrow) with 50 nl of a saturated calcium buffer (50 mM EGTA,
50 mM CaCl2, 50 mM HEPES (pH 7.3 with KOH); calculated free [Ca
2]  30 M after an
estimated 10-fold dilution in the cytoplasm). The activation of the PQAVAD mutant was
reduced significantly, compared with the wild type (n  5 each, p  0.05). (Statistical
difference of the activation of the distinct channels was determined with ANOVA fol-
lowed by pairwise comparisons with Scheffe’s test.)
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In the same experiment, by applying our newly discovered pharma-
cological tool, benzocaine, we also demonstrated that the mutations of
the PQIVID sequence really interfered with the process of activation
and did not render TRESK constitutively active. The benzocaine sensi-
tivity, measured after the ionomycin stimulation, was reduced in line
with the smaller responsiveness to the calcium signal.Whereas the wild
type TRESK current was inhibited by 57  2% (n  5), the sensitivity of
the PQIVIA, PQIVAD, and PQAVADmutantswas attenuated (44 1%
inhibition, n  5), strongly reduced (23  1%, n  5), and decreased
nearly to the level characteristic for the resting channels (18  1%, n 
5), respectively (Fig. 2A). These pharmacological data confirm the con-
clusion that themore severe is the perturbation of the bindingmotif, the
more impaired is the interactionwith calcineurin, and consequently, the
higher fraction of the mutant channels remains in the resting state after
the calcium signal.
To verify that the different levels of activation of TRESK mutants
were not due to the difference in the calcium signal, we measured the
endogenous calcium-activated chloride current (ICl,Ca), reflecting the
cytoplasmic [Ca2] of the oocytes. The amplitude of ICl,Ca, measured at
20mV in 80mM extracellular [K], 9–15 s after the administration of
ionomycin, was not significantly different in the oocytes expressing
the different TRESK mutants (data not shown). This indicates that the
reduced activation of TRESK mutants was not the consequence of the
altered Ca2 homeostasis of the cell, but it was the inherent property of
the mutant channels.
The Activation of the PQIVID Mutants Is Reduced Irrespective of the
Mechanism of the Calcium Signal—The levels of activation of the wild
type and mutant TRESK channels were also compared, when the cal-
cium signal was induced in amore physiologicalmanner, by stimulation
of M1 muscarinic ACh receptors, coexpressed with the channel. Whereas
carbachol (1M) activatedwild type TRESK efficiently, the response of the
PQIVIA, PQIVAD, and PQAVAD mutants were attenuated, strongly
reduced and eliminated, respectively (Fig. 2B), as in the case of stimula-
tion with ionomycin. These results suggest that the receptor-mediated
activation of TRESK also depends on the binding of calcineurin to the
PQIVID motif.
In Xenopus oocytes, ionomycin increases the cytoplasmic [Ca2]
mainly by releasing the ion from intracellular stores (22), and the stim-
ulation of M1 receptor also results in calcium release. To activate
TRESK independently from the calcium stores, the cytoplasmic [Ca2]
was controlled directly by microinjecting a saturated calcium buffer of
high (50 mM Ca2 plus 50 mM EGTA) concentration. The order of
responsiveness of wild type TRESK and the PQIVID mutants to the
microinjection was the same as those obtained with ionomycin and
carbachol (Fig. 2C). This indicates that the activation of TRESK may
generally rely on the intact PQIVID motif in the case of calcium signals
of different source and kinetics.
Microinjection of VIVIT Peptide Eliminates the Calcineurin-depend-
ent Activation of TRESK—The sequence of VIVIT peptide (MAGPH-
PVIVITGPHEE) was optimized for the highest affinity toward the
NFAT binding site of calcineurin (23). To provide a further in vivo
evidence for TRESK-calcineurin interaction in addition to TRESK
mutants, we also attempted to block the interaction by saturating the
NFAT binding site of calcineurin with VIVIT peptide. Xenopus oocytes
expressing wild type TRESK were microinjected with the peptide and
subsequently challenged with ionomycin. These oocytes failed to
respond with TRESK activation to the stimulation (Fig. 3A). The effec-
tive inhibition indicated that VIVIT peptide occupied the NFAT-dock-
ing site of calcineurin and thus prevented the binding of the intracellular
loop of TRESK, which would have normally interacted with the same
region of the phosphatase.
The dependence of TRESK regulation on calcineurin raised the
question whether the basal K current was also the result of the
calcineurin activity in the resting cell. To suppress the resting cal-
cineurin activity by reducing the cytoplasmic calcium concentration
to subphysiological levels, EGTA was microinjected to the oocytes
expressing TRESK, and the background K current was measured
before and after the microinjection. It was reported previously (3)
that the 50-nl injection of a high (50 mM) concentration of EGTA
was sufficient (even after the estimated 10-fold dilution of the che-
lator in the cytoplasm) to eliminate the calcium-dependent TRESK
activation. However, an identical EGTA injection failed to influence
unstimulated TRESK (Fig. 3B), indicating that a calcium-dependent
calcineurin activity did not contribute to the maintenance of the
basal TRESK current. As an alternative approach to extinguish the
possible basal calcineurin action on TRESK independently from cal-
cium, the TRESK-interacting surface of calcineurin was blocked with
VIVIT peptide. The microinjection of VIVIT peptide did not reduce
the basal TRESK current (Fig. 3B), also confirming that calcineurin
was not required for the resting TRESK activity.
The PQIVID Motif of TRESK Binds Constitutively Active Calcineurin
Permanently and Wild Type Calcineurin Calcium/Calmodulin-depen-
dently—To demonstrate the direct binding of the PQIVID motif of
TRESK to calcineurin, GST pulldown experiments were performed
with aGST-TRESKloop-TAPtag fusion protein (see “Experimental Pro-
cedures”), immobilized on glutathione-agarose beads. The constitu-
tively active form of calcineurin (A subunit lacking the autoinhibitory
domain and the calmodulin binding site but complexed with B subunit)
was incubated with this resin. The characteristic band of the truncated
calcineurin A could be easily detected with Coomassie Blue staining
(compare lanes 1 and 2 in Fig. 4A) if all proteins bound to the resin were
FIGURE 3. Microinjection of the VIVIT peptide eliminates the calcium-dependent
activation of TRESK but does not influence the current of the resting channel. A, two
groups of oocytes expressing wild type TRESK were microinjected with 50 nl of VIVIT
peptide (10 mM, n  5) or distilled water (Control, n  5), respectively. The oocytes were
stimulated with ionomycin (0.5 M) 23–104 min after the microinjection, as indicated by
the gray bar. TRESK currents were normalized to the resting value at the beginning of the
measurement. The activation in the two groups was statistically different at the end of
the measurement ( p  0.0001, Student’s t test for independent samples). B, oocytes
expressing wild type TRESK were microinjected with 50 nl of distilled water, high con-
centration of calcium chelator (50 mM EGTA, 50 mM HEPES (pH 7.3 with KOH)) or VIVIT
peptide (10 mM). TRESK currents of each oocyte were measured (at 100 mV by chang-
ing EC [K] from 2 to 80 mM and back) before and 54 –110 min after the microinjection.
The current measured after the injection was normalized to the initial value, and the
averages of the normalized currents of seven cells were plotted for each microinjected
solution. The effects of EGTA and VIVIT peptide microinjection on the basal TRESK cur-
rent were not significantly different from that of distilled water (ANOVA).
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analyzed on SDS-PAGE. To verify that calcineurin actually bound to the
PQIVID sequence, the experiment was carried out with the PQAVAD
mutant version of GST-TRESKloop-TAPtag under identical condi-
tions. In good accordance with the results obtained in the oocyte exper-
iments, the PQAVAD mutant GST-TRESKloop-TAPtag did not bind
the constitutively active calcineurin at all (compare lanes 3 and 4 in Fig.
4A). Moreover, the addition of VIVIT peptide (200 M) to the binding
reaction of the “wild type” (PQIVID) GST-TRESKloop-TAPtag also
eliminated the association with the constitutively active calcineurin
(Fig. 4B). These experiments indicate unequivocally that calcineurin
binds directly and specifically to the PQIVID motif of TRESK.
To gain further insight into the regulation of TRESK-calcineurin inter-
action, we also examined the binding of the full-length version of the phos-
phatase to the PQIVID motif. Since the calcineurin purified from bovine
brain has a larger molecular weight than its truncated recombinant coun-
terpart, the smaller GST-TRESKloop protein could be used in this pull-
down experiment. Apparently, full-length calcineurin bound to GST-
TRESKloop more strongly in the presence of the calcium/calmodulin
complex, and the specificity of this binding was also verified by the inhibi-
tory effect of VIVIT peptide (Fig. 4C). Thus the affinity of wild type cal-
cineurin to thePQIVIDmotif is enhancedby the activationof thephospha-
tase, and calcineurin may be recruited to TRESK during the physiological
activation by the calcium/calmodulin complex.
The Calcineurin Autoinhibitory Peptide Diminishes TRESK Activa-
tion but Does Not Interfere with the Binding of Calcineurin to the
PQIVIDMotif—As the binding of calcineurin to the PQIVIDmotif was
indispensable for TRESK activation, the question emerged whether this
binding was sufficient on its own or whether the phosphatase activity of
calcineurin was also required for the regulation. To suppress the phos-
phatase activity without occluding the protein-protein interaction, a
peptide corresponding to the autoinhibitory domain (467–491 amino
acids) of calcineurin was microinjected. This microinjection inhibited
the ionomycin-induced activation of wild type TRESK (Fig. 5A), sug-
gesting that the phosphatase activity of endogenous calcineurin was
required for TRESK activation.
To demonstrate that the autoinhibitory peptide did not influence the
binding of calcineurin to the PQIVIDmotif, recombinant constitutively
active calcineurin was used. We reported previously that the coexpres-
sion of the truncated calcineurin A subunit (1–398 amino acids, devoid
of the autoinhibitory domain) and full-length calcineurin Bwith TRESK
resulted in permanent activation of the channel (3). Inhibition of the
phosphatase activity by the reintroduction of the autoinhibitory domain
by peptide microinjection substantially reduced the otherwise perma-
nently stimulated TRESK current (Fig. 5B). On the other hand, the
autoinhibitory peptide, blocking only the active site of the phosphatase,
did not influence the binding of the constitutively active calcineurin to
the PQIVID motif in our GST pulldown experiments (compare lanes 3
and 4 in Fig. 5C). The reduction of TRESK current by the selective
inhibition of the phosphatase activity supports the conclusion that
dephosphorylation is also required for TRESK regulation in addition to
the binding of calcineurin to the PQIVID motif.
FIGURE 4. Calcineurin directly binds to the PQIVID motif of TRESK. A, GST pulldown
assays were performed with the wild type (PQIVID) GST-TRESKloop-TAPtag (wt.) or the
PQAVAD mutant (m.) version of the fusion protein in the presence or absence of consti-
tutively active calcineurin, as indicated at the bottom of the panel. In addition to TRESK
loop fusion protein (Full length), the expression resulted in additional bands, represent-
ing incomplete translation or bacterial protein degradation. One of these bands, slightly
larger than GST itself, was especially prominent, and it was marked as GST. The truncated
calcineurin A subunit (CnA1–398, 2.5 g, lane 5) was also indicated by an arrow. Note the
pulldown of calcineurin in lane 2 but not in lane 4. B, binding of the constitutively active
calcineurin to GST-TRESKloop-TAPtag was tested in the presence or absence of VIVIT
peptide (pept.) (200 M), as indicated at the bottom of the panel. In lane 4, only constitu-
tively active calcineurin (2.5 g) was loaded. The same bands as in A are indicated with
arrows. The lane of the markers was split, to introduce size labels. Note the pulldown of
calcineurin in lane 2 but not in lane 3. C, GST pulldown experiments were performed with
the wild type (PQIVID) GST-TRESKloop fusion protein, in the presence of calcium and in
the presence or absence of wild type calcineurin, calmodulin, and VIVIT peptide (200 M),
as indicated at the bottom of the panel. The full-length and incomplete fusion protein
(GST ) and wild type calcineurin A (CnA, 0.5 g, lane 1) are marked with arrows. Note the
binding of calcineurin in lane 4 (also indicated with an arrow and asterisk). (The repre-
sentative gels in A and B were stained with Coomassie Blue and in C with silver.)
FIGURE 5. The microinjection of calcineurin autoinhibitory peptide (autoinh. pept.)
reduces TRESK activation, but the peptide does not prevent the binding of cal-
cineurin to the PQIVID motif. A, two groups of oocytes expressing wild type TRESK
were microinjected with 50 nl of calcineurin autoinhibitory peptide (10 mM, n  4) or
distilled (dist.) water (Control, n  4), respectively. The oocytes were stimulated with
ionomycin (0.5 M, as indicated by the gray bar) 99 –158 min after the microinjection.
TRESK currents were normalized to the resting value at the beginning of the measure-
ment. The activation in the two groups was statistically different at the end of the meas-
urement ( p  0.05, Student’s t test for independent samples). B, wild type TRESK was
coexpressed with constitutively active calcineurin (truncated A subunit (amino acids
1–398) together with the full-length calcineurin B subunit; triple coexpression). Two
groups of oocytes, hereby expressing permanently stimulated TRESK channels, were
microinjected with 50 nl of calcineurin autoinhibitory peptide (10 mM, n  8) or distilled
water (n  7), respectively. TRESK current was measured before and 51–101 min after the
injection as detailed in Fig. 3B. The microinjection of the autoinhibitory peptide dimin-
ished significantly the K current, compared with the control water injection ( p  106,
Student’s t test for independent samples). C, binding of the constitutively active cal-
cineurin (CnA1–398) to GST-TRESKloop-TAPtag was tested in the presence or absence of
calcineurin autoinhibitory peptide (200 M), as indicated at the bottom of the panel. In
lane 1, only constitutively active calcineurin was loaded. The same bands as in Fig. 4B are
indicated with arrows. Note the pulldown of calcineurin in both lanes 3 and 4.
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DISCUSSION
Several proteins are substrates of calcineurin (24); however, only a
small subset of them interacts directly with the calcium/calmodulin-de-
pendent phosphatase through an NFAT-like docking site (13, 14,
25–27). Previously, we demonstrated unequivocally that the calcium-
dependent regulation of the two-pore domain K channel, TRESK, is
mediated by calcineurin (3). Alanine scanning mutagenesis of all intra-
cellular serine and threonine residues of TRESK indicated that Ser276,
located in the intracellular loop, is a likely candidate for dephosphoryl-
ation, since the S276A mutation, mimicking the dephosphorylated
state, rendered the channel constitutively active (3).
In the present study we report another aspect of TRESK-calcineurin
interaction. In addition to the enzyme-substrate relation, calcineurin
also binds to theNFAT-like PQIVIDmotif ofmouse TRESK. This bind-
ingmotif does not resemble the sites dephosphorylated by calcineurin at
all and it has been shown in the case of NFAT proteins that a surface of
the phosphatase, other than the substrate binding region, connects to
PXIXITmotifs (28). Interestingly, our GST pulldown experiments indi-
cated that the regulation of calcineurin activity essentially influenced
TRESK-calcineurin interaction. The constitutively active calcineurin
devoid of the autoinhibitory domain bound to the PQIVID motif per-
manently. In contrast, the binding of the wild type enzyme required (or
at least it was enhanced drastically by) the presence of calcium/calmod-
ulin complex. This substantial change of affinity may result in the shut-
tling of calcineurin between the cytoplasm and the PQIVID site during
the calcium signal.
Beyond the in vitro results, we provided compelling evidence that the
association of the two proteins is indispensable for the regulation of
TRESK in Xenopus oocytes. The channel was activated efficiently by
endogenous calcineurin, and the activation evolved even if TRESK was
expressed by injecting only a trace amount of cRNA (data not shown).
Thus TRESK-calcineurin interaction developed without the overex-
pression of the interacting partners. Identification of the well defined
NFAT-like motif also made it very unlikely that TRESK and calcineurin
interacted only by chance in our heterologous expression system. The
intracellular loops of the human and mouse TRESK orthologues show
only limited similarity. Still, the PQIVID motif aligns exceptionally well
to the PQIIIS sequence of human TRESK, and the two channels are
activated identically by the calcium signal, indicating that the binding
mechanism of calcineurin is evolutionary conserved.
In the present medical practice of organ transplantation, the phos-
phatase activity of calcineurin is inhibited for immunosuppression. To
eliminate the side effects of these treatments, significant effort has been
made to develop compounds, which inhibit NFAT activation but not
the phosphatase activity of calcineurin in general. In addition to VIVIT
peptide (23), a family of small molecule inhibitors blocking the NFAT
binding site of calcineurin has also been discovered (12). This novel class
of inhibitors (and possibly future drugs) is also expected to prevent
TRESK activation, in addition to the presently used immunosuppressive
agents, since TRESK and NFAT are complexed with calcineurin by the
same mechanism. Further research, elucidating the exact physiological
role of TRESK, will be required to determine, whether this cross-reac-
tion is advantageous or disadvantageous therapeutically. Elimination of
TRESK regulation may cause undesired symptoms or it may have an
auxiliary immunosuppressive effect, considering the reported expres-
sion of the channel in thymus and spleen.
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